MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

Search

Celsion Corp

Gesloten

0

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

Belangrijke statistieken

By Trading Economics

Werknemers

25

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+1233.33% upside

Dividenden

By Dow Jones

Volgende Winsten

12 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.3M

14M

Vorige openingsprijs

0

Vorige sluitingsprijs

0

Celsion Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 apr 2024, 14:38 UTC

Belangrijke Marktbewegers

Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine

Peer Vergelijking

Prijswijziging

Celsion Corp Prognose

Koersdoel

By TipRanks

1233.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14Ā USDĀ  1233.33%

Hoogste 14Ā USD

Laagste 14Ā USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celsion Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financieel

$

Over Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.